根据名称进行药物检索

Promacot与肝病

Promacot与肝病安全配伍检测的结果。

检测结果:

Promacot <> 肝病

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

吩噻有广泛代谢通过的肝脏可以积累在患有肝损害。此外，使用的一些吩噻已经与不利的影响，包括肝淤胆黄疸病和肝酶升高，一般在几个月的治疗。淤胆黄疸病通常发生在第二和第四个星期的治疗的大约0.1％到4％的所有患者。治疗与吩噻应给予谨慎地在患有先前存在的肝脏疾病、肝酶异常，或者乙型肝炎。肝功能和尿液胆红素试验应当进行定期过长时间的治疗和患者应当指示立即报告任何迹象或症状暗示的淤胆黄疸如上腹部疼痛、恶心的、黄色的皮肤，流感的症状、皮疹，以及发烧。吩治疗应该停止，最好的永久性，如果黄疸病发生的和可归因于药物。临床恢复是通常观察到几个星期内下列撤离的治疗，虽然组织病理学变化可能会持续更长的时间。

来源

"Product Information. Temaril (trimeprazine)" Allergan Inc, Irvine, CA.
Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980): 336-40
"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
"Product Information. Torecan (thiethylperazine)" Roxane Laboratories Inc, Columbus, OH.
Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982): 205-11
Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993): 353-8
Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988): 369-73
Simpson GM, Yadalam KG, Levinson DF, et al "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990): 417-21
"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.
"Product Information. Compazine (prochlorperazine)." SmithKline Beecham, Philadelphia, PA.
Hu OY, Tang H-S, Sheeng T-Y, et al "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990): 557-68
Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989): 1303-7
"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
"Product Information. Stelazine (trifluoperazine)" SmithKline Beecham, Philadelphia, PA.
Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and thrombocytopenia." Pharmacotherapy 4 (1984): 227-9
Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994): 30-6
Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966): 767-9
"Product Information. Vesprin (triflupromazine)" Bristol-Myers Squibb, Princeton, NJ.
Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981): 104-15
Podevin P, Biour M "Drug-induced ''allergic hepatitis''." Clin Rev Allergy Immunol 13 (1995): 223-44
"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
"Product Information. Serentil (mesoridazine)" Boehringer-Ingelheim, Ridgefield, CT.
Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967): 69-70
Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978): 187-96
"Product Information. Trilafon (perphenazine)" Schering Corporation, Kenilworth, NJ.
Maxwell JD, Carrella M, Parkes JD, et al "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972): 143-51
"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb, Princeton, NJ.
Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983): 287-93
Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994): 1437-41